Analysts have raised Prothena's fair value estimate by $1.00 to $13.00, citing improved profit margin forecasts and a slightly lower projected future price-to-earnings ratio.
What's in the News
- Prothena announced results from the Phase 1 ASCENT clinical program for PRX012 in early symptomatic Alzheimer's disease. The report highlighted reductions in amyloid plaque and outlined plans for potential partnership interest to advance PRX012 and its preclinical PRX012-TfR antibody (Key Developments).
- The results indicated that PRX012 demonstrated stable pharmacokinetics and low injection site reactions. However, there were higher rates of ARIA-E compared to FDA approved anti-amyloid beta antibodies (Key Developments).
- Prothena provided earnings guidance for 2025, projecting a net loss of $240 to $248 million, including significant non-cash expenses related to share-based compensation and income tax (Key Developments).
- A Special/Extraordinary Shareholders Meeting is scheduled for November 19, 2025, at the firm's offices in Dublin, Ireland (Key Developments).
Valuation Changes
- Fair Value Estimate increased from $12.00 to $13.00, reflecting a modest upward revision.
- Discount Rate edged up slightly, from 7.16% to 7.19%.
- Revenue Growth projection remains essentially unchanged at 109.9%.
- Net Profit Margin forecast improved, rising from 14.2% to 16.1%.
- Future P/E ratio forecast decreased from 57.75x to 55.07x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.